Contract analysis

I. Executive Summary and Purpose A. Purpose of This Memorandum The purpose of this memorandum is to outline the comprehensive federal regulatory obligations that will apply to Solstice Biomedical Inc. ("SBI," a Delaware corporation, File No. 7834291) and its Irish parent entity, Solstice Biomedical Devices Ltd. ("SBD," Companies Registration Office No. 648231), following the anticipated clearance by the United States

II. Medical Device Reporting (MDR) Under 21 C.F.R. Part 803

II.A. Overview of MDR Requirements Medical Device Reporting is among the most important post-market obligations for any manufacturer of cleared medical devices. The statutory basis for MDR is found in Section 519 of the Federal Food, Drug, and Cosmetic Act ("FD&C Act"), 21 U.S.C. § 360i, which grants FDA the authority to require manufacturers, importers, and device user facilities to report certain adverse events and

II.B. Reportable Events Under 21 C.F.R. § 803.50, a manufacturer must report to FDA when it becomes aware that a device it markets may have caused or contributed to a death or serious injury, or when it becomes aware of a malfunction that would be likely to cause or contribute to a death or serious injury if the malfunction were to recur. The three categories of reportable events are: Deaths. A manufacturer must repo

II.C. Reporting Procedures and Forms Manufacturer MDR reports are submitted on FDA Form 3500A (MedWatch Mandatory Reporting Form for manufacturers and importers). Form 3500A requires detailed information including patient demographics (to the extent known), device identification (including lot/serial number, model number, and UDI), a narrative description of the event, and the manufacturer's evaluation and conclusion

II.D. Supplemental, Follow-Up, and Baseline Reports Supplemental Reports. Under 21 C.F.R. § 803.56, a manufacturer that has submitted an MDR report must submit a supplemental report within thirty (30) days of receiving or becoming aware of any information that was not provided in the initial report and that is required to be reported under Part 803. This includes additional investigation findings, patient outcome inf

II.E. Coordination with EU Vigilance Reporting Solstice already maintains vigilance reporting systems under EU MDR Article 87 for the Lumina CGM System, which has been commercially available in the European Union since September 2024. The EU vigilance reporting framework requires manufacturers to report serious incidents involving devices placed on the EU market through the EUDAMED database (or, pending full EUDAMED

III. Corrections and Removals Under 21 C.F.R. Part 806

III.A. Definitions and Scope When a manufacturer identifies a problem with a device that has already been distributed, it may need to take corrective action. The FDA's reporting requirements for such actions are set forth in 21 C.F.R. Part 806, which governs reports of corrections and removals. Understanding the precise definitions under this regulation is essential, as they determine whether a particular action trig

III.B. Reporting Requirements When a manufacturer initiates a correction or removal of a device to reduce a risk to health posed by the device, or to remedy a violation of the FD&C Act caused by the device that may present a risk to health, the manufacturer must submit a written report to FDA within ten (10) working days of initiating the correction or removal. 21 C.F.R. § 806.10. The reporting obligation does not ap

III.C. Practical Considerations for Lumina CGM System Given the Lumina CGM System's combination of hardware, software, and implantable components, SBI should anticipate a range of scenarios that could give rise to corrections or removals. The following considerations are particularly relevant: Software-Related Corrections. The Lumina CGM System includes multiple software components: Firmware v3.4.2 (embedded in the C

IV. Quality System Regulation (QSR) Compliance Under 21 C.F.R. Part 820

IV.A. Applicability and Overview The current Quality System Regulation (QSR), codified at 21 C.F.R. Part 820, establishes the quality management system requirements for manufacturers of finished medical devices marketed in the United States. Compliance with the QSR is a legal obligation under Section 520(f) of the FD&C Act, and failure to comply can result in FDA warning letters, consent decrees, injunctions, device

IV.B. Key QSR Subsystems Relevant to Lumina CGM System

IV.B.1. Management Responsibility (21 C.F.R. § 820.20) Under § 820.20, management with executive responsibility must establish its quality policy and objectives, and must ensure that the quality policy is understood, implemented, and maintained at all levels of the organization. Management must also establish an appropriate organizational structure, identify the resources necessary to meet quality requirements, appoi

IV.B.2. Design Controls (21 C.F.R. § 820.30) Design controls are among the most critical QSR requirements for the Lumina CGM System. Under § 820.30, manufacturers of Class II devices (and all Class III devices) must establish and maintain procedures to control the design of the device to ensure that specified design requirements are met. Design controls apply to the entire design process, from initial concept through

IV.B.3. Document Controls (21 C.F.R. § 820.40) SBI and SBD must establish and maintain procedures to control all documents required by the QSR. This includes procedures for document approval and distribution (§ 820.40(a)) and document changes (§ 820.40(b)). All quality system documents must be reviewed and approved by a designated individual(s) before issuance, and changes to documents must be reviewed and approved b

IV.B.4. Purchasing Controls (21 C.F.R. § 820.50) Under § 820.50, manufacturers must establish and maintain procedures to ensure that all purchased or otherwise received products and services conform to specified requirements. This includes establishing requirements for suppliers, evaluating and selecting suppliers based on their ability to meet specified requirements, and defining the type and extent of control to be

IV.B.5. Production and Process Controls (21 C.F.R. §§ 820.70–820.75) Production and process controls require that manufacturers develop, conduct, control, and monitor production processes to ensure that the device conforms to its specifications. This includes: • Production and process controls (§ 820.70): Control of process parameters and component handling to ensure conformance to specifications. Where results canno

IV.B.6. Acceptance Activities (21 C.F.R. §§ 820.80, 820.86) Under § 820.80, manufacturers must establish and maintain procedures for acceptance activities, including receiving acceptance (incoming inspection of components and materials), in-process acceptance (inspection and testing during manufacturing), and finished device acceptance (final inspection and testing of completed devices). Acceptance activities must en

IV.B.7. Corrective and Preventive Action (CAPA) (21 C.F.R. § 820.90) The CAPA subsystem is frequently the focus of FDA inspections and is one of the areas where manufacturers most commonly receive citations. Under § 820.90, manufacturers must establish and maintain procedures for: (a) Analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned produ

IV.B.8. Labeling and Packaging Controls (21 C.F.R. §§ 820.120, 820.130) Under § 820.120, manufacturers must establish and maintain procedures to control labeling activities, including label integrity, labeling inspection, labeling storage, and labeling operations. Label integrity requirements are designed to prevent mix-ups between labels for different products or different versions of the same product. Given that th

IV.B.9. Complaint Handling (21 C.F.R. § 820.198) Under § 820.198, manufacturers must establish and maintain procedures for receiving, reviewing, and evaluating complaints. A "complaint" is broadly defined as any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distr

IV.B.10. Servicing (21 C.F.R. § 820.200) Under § 820.200, manufacturers that service medical devices must establish and maintain instructions and procedures for performing and verifying that servicing meets specified requirements. This requirement is applicable to SBI to the extent that SBI services the R7 Reader (e.g., warranty repairs, hardware replacements, firmware updates performed by service personnel) or provi

IV.B.11. Records and DHR/DMR/DHF Requirements The QSR requires manufacturers to establish and maintain several categories of records that are fundamental to demonstrating quality system compliance: • Device History Record (DHR) (§ 820.184): A compilation of records containing the production history of a finished device. The DHR must include, or refer to the location of, the dates of manufacture, the quantity manufact

IV.C. Gap Analysis: ISO 13485:2016 vs. 21 C.F.R. Part 820 Solstice currently holds ISO 13485:2016 certification, certified by Meridian Conformity Assessment GmbH (NB 0483). ISO 13485:2016 and 21 C.F.R. Part 820 share a common heritage and have substantial overlap — both establish requirements for a comprehensive quality management system covering management responsibility, resource management, product realization, an

IV.D. FDA Inspection Readiness FDA has the authority to inspect any establishment that manufactures, processes, packs, or holds medical devices for U.S. distribution. Inspections may occur pre-clearance (as part of the 510(k) review process, though this is relatively uncommon for 510(k) submissions) or post-clearance (either as a routine surveillance inspection or as a "for-cause" inspection triggered by a specific c

V. Transition from QSR to Harmonized ISO 13485 Rule (QMSR)

V.A. Background on FDA's Quality Management System Regulation (QMSR) Final Rule On February 2, 2024, FDA published the final rule amending 21 C.F.R. Part 820 to incorporate by reference ISO 13485:2016 as the quality management system standard for medical devices (the "Quality Management System Regulation" or "QMSR"). This rulemaking represents a fundamental shift in FDA's approach to quality system regulation, replac